Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Fremanezumab (Ajovy) and Rimegepant (Nurtec) — clinical data, side effects, and patient experiences.
Ajovy · CGRP Inhibitor (Migraine)
How it works
Humanized monoclonal antibody that selectively binds to CGRP ligand, preventing activation of the CGRP receptor.
Approved for
Nurtec · CGRP Antagonist (Gepant)
How it works
Small molecule CGRP receptor antagonist that blocks CGRP signalling, used for both acute treatment and prevention of migraine.
Approved for
Estimated frequency (%) based on clinical trial data
No specific warnings
No head-to-head clinical studies found for Fremanezumab vs Rimegepant.
Fremanezumab is a CGRP Inhibitor (Migraine), while Rimegepant belongs to the CGRP Antagonist (Gepant) class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. Fremanezumab is administered via Subcutaneous, whereas Rimegepant uses Oral. Route of administration can affect onset of action and patient adherence.
Both medications are approved for Migraine Prevention. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
Fremanezumab carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.